COHANCE LIFESCIENCES LTD
Fundamental Score
COHANCE LIFESCIENCES LTD Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of COHANCE across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (40.21%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Conservative Debt Levels (D/E: 0.12)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (14.48x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹1137.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (57.49%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 27.32%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Risk Factors
9 factors identified
Premium Valuation Risk (P/E: 61.57x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-46.50%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-7.98%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Earnings Growth (-5.33% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-5.33% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
High Share Pledging Risk (100.00%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for COHANCE LIFESCIENCES LTD
About COHANCE
Business Overview
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Company Details
Key Leadership
Corporate Events
COHANCE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of COHANCE LIFESCIENCES LTD (COHANCE)?
As of 29 Jan 2026, 10:36 am IST, COHANCE LIFESCIENCES LTD (COHANCE) is currently trading at ₹378.40. The stock has a market capitalization of ₹21.15K (Cr).
Is COHANCE share price Overvalued or Undervalued?
COHANCE is currently trading at a P/E ratio of 61.57x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the COHANCE LIFESCIENCES LTD share price?
Key factors influencing COHANCE's price include its quarterly earnings growth (Sales Growth: -7.98%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is COHANCE LIFESCIENCES LTD a good stock for long-term investment?
COHANCE LIFESCIENCES LTD shows a 5-year Profit Growth of -5.33% and an ROE of 12.67%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.12 before investing.
How does COHANCE LIFESCIENCES LTD compare with its industry peers?
COHANCE LIFESCIENCES LTD competes with major peers in the Pharmaceuticals. Investors should compare COHANCE's P/E of 61.57x and ROE of 12.67% against the industry averages to determine its competitive standing.
What is the P/E ratio of COHANCE and what does it mean?
COHANCE has a P/E ratio of 61.57x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹62 for every ₹1 of annual earnings.
How is COHANCE performing according to Bull Run's analysis?
COHANCE has a Bull Run fundamental score of 10.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does COHANCE belong to?
COHANCE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting COHANCE LIFESCIENCES LTD.
What is Return on Equity (ROE) and why is it important for COHANCE?
COHANCE has an ROE of 12.67%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently COHANCE LIFESCIENCES LTD generates profits from shareholders' equity.
How is COHANCE's debt-to-equity ratio and what does it indicate?
COHANCE has a debt-to-equity ratio of 0.12, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is COHANCE's dividend yield and is it a good dividend stock?
COHANCE offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has COHANCE grown over the past 5 years?
COHANCE has achieved 5-year growth rates of: Sales Growth 7.51%, Profit Growth -5.33%, and EPS Growth -5.33%.
What is the promoter holding in COHANCE and why does it matter?
Promoters hold 57.49% of COHANCE shares, with 100.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is COHANCE's market capitalization category?
COHANCE has a market capitalization of ₹21150 crores, placing it in the Large-cap category.
How volatile is COHANCE stock?
COHANCE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for COHANCE?
COHANCE has a 52-week high of ₹N/A and low of ₹N/A.
What is COHANCE's operating profit margin trend?
COHANCE has a 5-year average Operating Profit Margin (OPM) of 40.21%, indicating the company's operational efficiency.
How is COHANCE's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -7.98% and YoY Profit Growth of -46.50%.
What is the institutional holding pattern in COHANCE?
COHANCE has FII holding of 6.51% and DII holding of 20.81%. Significant institutional holding often suggests professional confidence in the stock.